Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

June 28, 2019 9:56 PM UTC

AZ's Imfinzi shows survival benefit in Phase III for SCLC
AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint of improving overall survival (OS) vs. chemotherapy alone to treat first-line extensive-stage small cell lung cancer. The anti-PD-L1 mAb is approved for bladder cancer and non-small cell lung cancer (NSCLC).
Rivoceranib misses in gastric cancer Phase III
LSK BioPharma Inc. (Salt Lake City, Utah) said rivoceranib failed to improve OS among third-line patients with gastric cancer, missing the primary endpoint of the international Phase III ANGEL study. The VEGFR-2 inhibitor did beat placebo on a secondary endpoint measuring progression-free survival (PFS). Rivoceranib is in Phase I/II testing as a second-line therapy for gastric cancer, as well as other clinical trials for other cancers. LSK is developing the drug outside of China, where Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) markets it as Aitan apatinib for third-line gastric cancer.

Setback for Revatio in neonatal pulmonary hypertension
Pfizer Inc. (NYSE:PFE) said IV Revatio sildenafil plus inhaled nitric oxide (iNO) compared with iNO alone failed to reduce treatment failure rate and time on iNO, the co-primary endpoints, in the interventional Part A of a Phase III trial to treat neonates with persistent pulmonary hypertension. The non-interventional Part B of the trial evaluating developmental progress is ongoing...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article